Phage therapy firm Ampliphi to list on NYSE

By Gareth Macdonald contact

- Last updated on GMT

Phage firm Ampliphi to list on NYSE
Phage firm Ampliphi to list on NYSE

Related tags: Bacteria

Phage therapy developer AmpliBphi Biosciences has been cleared to list on the New York Stock Exchange’s MKT market.

The approval, which was announced last night, will see the bacteriophage focused drug developer’ shares begin trading on August 21.

The firm’s recently appointed CEO, Michael Scott Salka, said: “The NYSE MKT listing represents a key milestone for AmpliPhi on our mission to develop novel bacteriophage-based treatments to combat the growing global threat posed by antibiotic-resistant bacteria​.”

Back from the USSR

Ampliphi Biosciences develops anti-infective therapies based on bacterial viruses – known as bacteriophage - as alternatives to antibiotics. 

Phage therapy ​was used extensively in the Soviet Union as access to antibiotics developed in the West was limited.

While the approach is still used in Russia and other former eastern bloc countries, it has never caught on elsewhere.

Quite why is unclear, although researchers like phage expert Mzia Kutateladze ​from the Eliava Institute in Tbilisi, Georgia have suggested that (unfounded) concerns about using viruses to treat disease were a factor.

For others it is because, unlike their Soviet counterparts, Western doctors have always had access to antibiotics.

But in recent years this has started to change as bacteria have become resistant to antibiotics, prompting renewed interest in phage therapies.

News of the listing comes a few months after Ampliphi’s bacteriophage therapy production facility in Ljubljana was deemed to meet manufacturing standards by Slovenian regulators.

Related news

Show more

Related products

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more